Invited commentary: thirty-five years of leaky vaccines

被引:0
作者
Halloran, M. Elizabeth [1 ,2 ]
Struchiner, Claudio J. [3 ,4 ]
机构
[1] Fred Hutchinson Canc Ctr, Biostat Bioinformat & Epidemiol Program, Vaccine & Infect Dis Div, Seattle, WA 98109 USA
[2] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA
[3] Fdn Getulio Vargas, Escola Matemat Aplicada, BR-22250145 Rio De Janeiro, Brazil
[4] Univ Estado Rio de Janeiro, Inst Med Social, BR-20550300 Rio De Janeiro, Brazil
关键词
leaky; malaria; vaccine; vaccine efficacy; MODELING MALARIA VACCINES; EFFICACY;
D O I
10.1093/aje/kwae379
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Over the past 35 years, the term "leaky vaccine" has gained widespread use in both mathematical modeling and epidemiologic methods for evaluating vaccines. Here, we present a short history, as we recall it, of how the term was coined in the context of the history of sporozoite malaria vaccines that were thought in the 1980s to be possibly leaky. We draw a contrast with the all-or-none vaccine mechanism and review a few consequences for study design and population-level effects. We invite readers to contribute information covering the period preceding our memories in the 1980s, because we may have overlooked something.
引用
收藏
页码:918 / 920
页数:3
相关论文
共 15 条
[1]   Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, doubleblind, randomised, phase 3 trial [J].
Datoo, Mehreen S. ;
Dicko, Alassane ;
Tinto, Halidou ;
Ouedraogo, Jean-Bosco ;
Hamaluba, Mainga ;
Olotu, Ally ;
Beaumont, Emma ;
Lopez, Fernando Ramos ;
Natama, Hamtandi Magloire ;
Weston, Sophie ;
Chemba, Mwajuma ;
Compaore, Yves Daniel ;
Issiaka, Djibrilla ;
Salou, Diallo ;
Some, Athanase M. ;
Omenda, Sharon ;
Lawrie, Alison ;
Bejon, Philip ;
Rao, Harish ;
Chandramohan, Daniel ;
Roberts, Rachel ;
Bharati, Sandesh ;
Stockdale, Lisa ;
Gairola, Sunil ;
Greenwood, Brian M. ;
Ewer, Katie J. ;
Bradley, John ;
Kulkarni, Prasad S. ;
Shaligram, Umesh ;
Hill, Adrian V. S. .
LANCET, 2024, 403 (10426) :533-544
[2]  
DIETZ K, 1974, B WORLD HEALTH ORGAN, V50, P347
[3]  
Greenwood M, 1915, Proc R Soc Med, V8, P113
[4]  
Halloran ME, 2010, STAT BIOL HEALTH, P271, DOI 10.1007/978-0-387-68636-3_13
[5]  
Halloran ME, 1996, AM J EPIDEMIOL, V144, P83, DOI 10.1093/oxfordjournals.aje.a008858
[6]   MODELING MALARIA VACCINES .2. POPULATION EFFECTS OF STAGE-SPECIFIC MALARIA VACCINES DEPENDENT ON NATURAL BOOSTING [J].
HALLORAN, ME ;
STRUCHINER, CJ ;
SPIELMAN, A .
MATHEMATICAL BIOSCIENCES, 1989, 94 (01) :115-149
[7]   STUDY DESIGNS FOR DEPENDENT HAPPENINGS [J].
HALLORAN, ME ;
STRUCHINER, CJ .
EPIDEMIOLOGY, 1991, 2 (05) :331-338
[8]   RTS,S/AS01 vaccine (Mosquirix?): an overview [J].
Laurens, Matthew B. .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (03) :480-489
[9]  
Longini IM, 1996, J ROY STAT SOC C, V45, P165
[10]  
Molineaux L., 1980, The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa.